skip to main content
  • February 12, 2019

    Biology of tumour changes when childhood brain cancer recurs, Canadian study finds

    New research co-funded by the Terry Fox Research Institute offers a simple explanation as to why new and experimental treatments fail for children with recurrent medulloblastoma, the most common cancerous brain tumour in children. The study was conducted by The Hospital for Sick Children (SickKids) and the BC Cancer Agency and is part of the Medulloblastoma Advanced Genomics International Consortium (MAGIC) project.

  • February 12, 2019

    Terry Fox award helps Ottawa researcher develop next-generation cancer immunovirotherapy

    What if there was a way to destroy cancer cells and stimulate a patient’s own immune system to attack tumours, while leaving healthy tissues unharmed? The Terry Fox Research Institute (TFRI) has awarded Dr. Guy Ungerechts (The Ottawa Hospital and the University of Ottawa) a $450,000 New Investigator grant to develop innovative new treatments to achieve just that.

  • January 15, 2019

    Restoring stem cells to a fetal-like state could provide a therapeutic alternative for acute leukemias

    A team of TFRI-funded scientists in Vancouver has discovered that restoring a signaling pathway that is prevalent in fetal stem cells but dormant in adult ones may provide an alterative treatment for acute T-cell leukemia (T-ALL).

  • January 15, 2019

    CEST MRI may be able to measure patient response to chemotherapy within 24 hours after first dosage

    TFRI researchers at Sunnybrook Hospital have found that CEST MRI technology can be used to detect cancer cell death in mice within 24 hours of receiving chemotherapy, much sooner than current methods.

  • January 15, 2019

    New finding suggests that disrupting interaction between MYC and G9a could stop cancer growth

    New technology has helped a TFRI-funded multidisciplinary research team identify how MYC – a key driver of human cancer – works, cracking open the possibility for new targets and treatments to stop it in its tracks.

  • January 15, 2019

    Montreal research team identifies SREBF1 as a new, targetable regulatory pathway in prostate cancer

    The newly discovered pathway, SREBF1, was found to be directly responsible for controlling prostate cancer cell metabolism. It can be targeted with several pharmacological approaches already in use to treat other diseases.

  • January 15, 2019

    Study reveals genomic differences between long- and short- term survivors of high-grade serous ovarian cancer, advancing potential for individualized treatments

    Researchers may be one step closer to personalizing treatments for patients with high-grade serous ovarian cancer thanks to a new study that revealed several clinical and genomic biomarkers that could help predict response to standard-of-care treatment.

  • January 15, 2019

    Use of mTOR inhibitors increases efficacy of herpes virus as an oncolytic therapy

    A new study by a team of TFRI-funded scientists has found that combining a particular strain of the herpes virus with mTOR inhibitors improves viral replication within tumour cells with dysregulated protein synthesis, boosting the virus’ cancer-killing ability.

  • January 15, 2019

    Pan-Canadian prostate cancer team creates robust resource tool to help clinicians with treatment decision-making

    A pan-Canadian prostate cancer group funded by the TFRI team has created a new tissue microarray (TMA)-based resource to assist clinicians and pathologists in validating biomarkers for patients with prostate cancer.

  • January 15, 2019

    Study shows benefit of vascular normalization in OV therapy for advanced epithelial ovarian cancer

    Immunologists at the University of Guelph have discovered that normalizing blood flow into tumours improves efficacy of oncolytic viruses, departing from long-held beliefs about the benefits of acute vascular shutdown.

  • January 15, 2019

    Dr. David Eisenstat appointed Alberta Node Leader for TFRI

    The Terry Fox Research Institute is pleased to announce the appointment of Dr. David Eisenstat as its new node leader for the Province of Alberta.

  • January 14, 2019

    Researchers discover common markers of tumour hypoxia across 19 cancer types

    The study, which was partially funded by the TFRI, investigated more than 8,000 human tumours across 19 different cancer types, including prostate tumours from the Canadian Prostate Cancer Genome Network (CPC-GENE). The authors discovered common markers of hypoxia that could help predict cancer aggressiveness and inform treatment decisions.

  • December 10, 2018

    Outstanding researchers from Montreal, Halifax and Toronto receive $1.35 million to find new treatments for metastatic and ovarian cancers

    Three outstanding early-career investigators from Montreal, Halifax and Toronto will each receive $450,000 over the next three years to explore new treatments for metastatic cancers like the one Terry Fox had and identify ways that immunotherapy can help ovarian cancer patients.

  • December 03, 2018

    Identification of new lymphoma sub-group by Terry Fox Research Institute-funded cancer researchers opens door for potential new treatments for hard-to-treat cancer

    The discovery by BC researchers of a group of bad actors ‘hidden’ within a cohort of good ones may translate into new hope for cancer patients diagnosed with a type of lymphoma that doesn’t respond well to treatment.

  • November 14, 2018

    TFRI BC Node researchers present their work during 2018 BC Cancer Summit

    The Terry Fox Research Institute's BC Node will host its annual Node Day on Friday, Nov. 23, 2018 at the Sheraton Wall Centre in Vancouver.

Back to Top